Healthtech VCLink’s Post

In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar.

In the evolving landscape of weight loss solutions, Allurion’s intragastric balloon shows remarkable promise, with patients shedding an average of 17% of their body weight within six months. However, the rise of GLP-1 drugs like Wegovy and Mounjaro casts a long shadow over its success. These injectable medications have become the go-to for long-term weight management, largely due to their sustained effectiveness and ease of use. While Allurion offers a non-invasive, short-term option, sustaining weight loss post-balloon remains a challenge, creating a gap that GLP-1s effectively bridge. As the weight-loss market shifts, Allurion faces not just competition but significant financial hurdles, including a potential NYSE delisting. The future might lie in niche markets or combination therapies. Can Allurion carve out its space amid GLP-1 dominance? The battle for weight loss superiority is just heating up. Your thoughts?

K-CAB success boosts HK inno.N’s operating profit, doubling in H1 2024 - HK inno.N Q2 sales reach KRW 219.3 billion with operating profit totaling KRW 24.3 billion, YoY increase of 7.3% and 58.9%, respectively - K-CAB achieves record highest outpatient prescription sales of KRW 46.6 billion in Q2 https://lnkd.in/g59REy4i

In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar.

My take on the not-so-Faustian deal to bring MDMA to market. Whatever happens, life will surely be much better with ecstasy prescriptions https://lnkd.in/ea44tB53

💡 Have you ever thought of delivering drugs through catheter? 📌 Catheter coatings containing medication offer a promising advancement in drug delivery through catheters. These coatings can be applied to various catheters, including urinary catheters, intravenous (IV) catheters, and central venous catheters. 📍 Boston Scientific has received Food and Drug Administration approval for a drug-coated balloon to treat coronary in-stent restenosis, a condition in which a vessel that previously received a stent narrows again due to plaque or scar tissue 📍In-stent restenosis occurs in about 10% of U.S. patients who receive a percutaneous coronary intervention procedure to open clogged heart arteries 📍 The balloon catheter is coated with the drug paclitaxel and transfers a dose to the vessel wall to help prevent it from narrowing again. 📍The advantages by delivering drug through catheter include Targeted drug delivery, Improved efficacy, Reduced need for additional medications #bostonscientific #drugdevicecombinations#restenosis

According to the Cleveland Clinic, about 2% of the U.S. workforce is disabled due to back pain, leaving them unable to perform daily tasks. Back pain shouldn't hold you back from enjoying life to the fullest. With Gladiator Therapeutics, you can finally experience the relief you deserve. Learn more about our Gladiator MD™ Abdomen/Back Device. https://ow.ly/W6yh50R2By5 #GladiatorTherapeutics #FarInfrared #BackPain #BackInjury #Back #Injury #PatentedDevices

KYZATREX® (testosterone undecanoate) CIII capsules are now available at Gameday Men’s Health clinics across 48 states! This partnership expands access to the FDA-approved oral testosterone therapy, offering a convenient, non-invasive option for men with testosterone deficiency. Together, Marius Pharmaceuticals and Gameday Men’s Health are empowering men to prioritize their health and vitality. Read the full press release here: https://lnkd.in/eMmFYtcc KYZATREX® (testosterone undecanoate) is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions. KYZATREX is not for use in males less than 18 years old. KYZATREX is not meant for use by women. Rx only. See full PI, Med Guide, & Boxed Warning for risk of increased blood pressure at www.kyzatrex.com.

The newly approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) gives #multiplesclerosis (MS) patients a faster, more accessible treatment option with its 10-minute subcutaneous injection. Learn more about the new flexible, patient-friendly treatment here: https://buff.ly/3B39cPg #FDAApproval #FDA #OcrevusZunovo #Genentech

The newly approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) gives #multiplesclerosis (MS) patients a faster, more accessible treatment option with its 10-minute subcutaneous injection. Learn more about the new flexible, patient-friendly treatment here: https://buff.ly/3B39cPg #FDAApproval #FDA #OcrevusZunovo #Genentech